Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy

Figure 1 Patients selected and outcome of infliximab therapy. CD: Crohn‘s disease; EA: Endoscopic activity; IFX: Infliximab.

Figure 2 Incremental gain analysis of sustained endoscopic remission rate in relation to infliximab trough level at week 14 and week 54.

Figure 3 Receiver operator characteristic curve of infliximab trough level and inflammatory biomarkers in predicting endoscopic outcomes. A: Receiver operator characteristic (ROC) curve of infliximab trough level at week 14 in predicting endoscopic remission of Crohn’s disease (CD) at week 54; B: ROC curve of fecal calprotectin at week 14 in predicting endoscopic remission of CD at week 54; C: ROC curve of infliximab trough level at week 54 in predicting endoscopic remission of CD at week 108; D: ROC of C-reactive protein at week 54 in predicting endoscopic remission of CD at week 108. ITL: Infliximab trough level; CRP: C-reactive protein; FCP: Fecal calprotectin; AUC: Area under the curve.

Figure 4 Proportion without endoscopic relapse. A. Time since infliximab (IFX) therapy at week 14 [IFX trough level (ITL) > 5.6 μg/mL vs ITL ≤ 5.6 μg/mL]; B: Time to IFX therapy at week 14 (fecal calprotectin ≤ 238 μg/g vs fecal calprotectin > 238 μg/g]; C: Time to IFX therapy at week 54 (C-reactive protein ≤ 3.0mg/L vs C-reactive protein > 3.0 mg/L); D: Time to IFX therapy at week 54 (ITL > 2.1 μg/mL vs ITL ≤ 2.1 μg/mL). ITL: Infliximab trough level; CRP: C-reactive protein; FCP: Fecal calprotectin; IFX: Infliximab.